Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer
| dc.contributor.author | Kartal Yandim, Melis | |
| dc.contributor.author | Adan Gökbulut, Aysun | |
| dc.contributor.author | Baran, Yusuf | |
| dc.date.accessioned | 2025-09-25T10:51:03Z | |
| dc.date.available | 2025-09-25T10:51:03Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Chemotherapy is the main strategy for the treatment of cancer. However, the main problem limiting the success of chemotherapy is the development of multidrug resistance. The resistance can be intrinsic or acquired. The resistance phenotype is associated with the tumor cells that gain a cross-resistance to a large range of drugs that are structurally and functionally different. Multidrug resistance arises via many unrelated mechanisms, such as overexpression of energy-dependent efflux proteins, decrease in uptake of the agents, increase or alteration in drug targets, modification of cell cycle checkpoints, inactivation of the agents, compartmentalization of the agents, inhibition of apoptosis and aberrant bioactive sphingolipid metabolism. Exact elucidation of resistance mechanisms and molecular and biochemical approaches to overcome multidrug resistance have been a major goal in cancer research. This review comprises the mechanisms guiding multidrug resistance in cancer chemotherapy and also touches on approaches for reversing the resistance. © 2017 Elsevier B.V., All rights reserved. | en_US |
| dc.identifier.doi | 10.3109/07388551.2015.1015957 | |
| dc.identifier.issn | 1549-7801 | |
| dc.identifier.issn | 0738-8551 | |
| dc.identifier.scopus | 2-s2.0-84942314013 | |
| dc.identifier.uri | https://doi.org/10.3109/07388551.2015.1015957 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12573/4231 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor and Francis Ltd healthcare.enquiries@informa.com | en_US |
| dc.relation.ispartof | Critical Reviews in Biotechnology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Abc Transporters | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Bioactive SPHingolipids | en_US |
| dc.subject | Cancer | en_US |
| dc.subject | Cell Cycle Alteration | en_US |
| dc.subject | Multidrug Resistance | en_US |
| dc.subject | Multidrug Resistance Protein | en_US |
| dc.subject | PhoSPHatidylinositol 3,4,5 TriSPhosphate 3 PhoSPHatase | en_US |
| dc.subject | Protein Bcl 2 | en_US |
| dc.subject | SPHingosine 1 Phosphate | en_US |
| dc.subject | Antineoplastic Agents | en_US |
| dc.subject | Membrane Lipids | en_US |
| dc.subject | Cell Death | en_US |
| dc.subject | Chemotherapy | en_US |
| dc.subject | Drug Therapy | en_US |
| dc.subject | Abc Transporter | en_US |
| dc.subject | Cancer | en_US |
| dc.subject | Cell Cycle | en_US |
| dc.subject | Multidrug Resistance | en_US |
| dc.subject | SPHingolipids | en_US |
| dc.subject | Diseases | en_US |
| dc.subject | Antineoplastic Agent | en_US |
| dc.subject | Breast Cancer Resistance Protein | en_US |
| dc.subject | Glucosylceramide | en_US |
| dc.subject | Membrane Lipid | en_US |
| dc.subject | Multidrug Resistance Protein | en_US |
| dc.subject | PhoSPHatidylinositol 3,4,5 TriSPhosphate 3 PhoSPHatase | en_US |
| dc.subject | Protein Bcl 2 | en_US |
| dc.subject | Protein P53 | en_US |
| dc.subject | SPHingosine 1 Phosphate | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Cancer Cell | en_US |
| dc.subject | Cancer Chemotherapy | en_US |
| dc.subject | Cell Compartmentalization | en_US |
| dc.subject | Clinical Trial (Topic) | en_US |
| dc.subject | Drug Accumulation | en_US |
| dc.subject | Drug Inactivation | en_US |
| dc.subject | Drug Targeting | en_US |
| dc.subject | Drug Uptake | en_US |
| dc.subject | Human | en_US |
| dc.subject | Multigene Family | en_US |
| dc.subject | Neoplasm | en_US |
| dc.subject | Phase 1 Clinical Trial (Topic) | en_US |
| dc.subject | Phase 2 Clinical Trial (Topic) | en_US |
| dc.subject | Phase 3 Clinical Trial (Topic) | en_US |
| dc.subject | Priority Journal | en_US |
| dc.subject | Review | en_US |
| dc.subject | Cell Cycle | en_US |
| dc.subject | Metabolism | en_US |
| dc.subject | Multidrug Resistance | en_US |
| dc.subject | Neoplasms | en_US |
| dc.subject | Antineoplastic Agents | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Cell Cycle | en_US |
| dc.subject | Drug Resistance, Multiple | en_US |
| dc.subject | Humans | en_US |
| dc.subject | Membrane Lipids | en_US |
| dc.title | Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.scopusid | 37050733400 | |
| gdc.author.scopusid | 55570805200 | |
| gdc.author.scopusid | 9636164400 | |
| gdc.bip.impulseclass | C3 | |
| gdc.bip.influenceclass | C4 | |
| gdc.bip.popularityclass | C3 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | Abdullah Gül University | en_US |
| gdc.description.departmenttemp | [Kartal Yandim] Melis, Department of Molecular Biology and Genetics, Izmir Yüksek Teknoloji Enstitüsü, Izmir, Turkey; [Adan Gökbulut] Aysun, Department of Molecular Biology and Genetics, Izmir Yüksek Teknoloji Enstitüsü, Izmir, Turkey; [Baran] Yusuf, Department of Molecular Biology and Genetics, Izmir Yüksek Teknoloji Enstitüsü, Izmir, Turkey, Faculty of Life and Natural Sciences, Abdullah Gül Üniversitesi, Kayseri, Turkey | en_US |
| gdc.description.endpage | 726 | en_US |
| gdc.description.issue | 4 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 716 | en_US |
| gdc.description.volume | 36 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W1990665786 | |
| gdc.identifier.pmid | 25757878 | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 131 | |
| gdc.oaire.impulse | 42.0 | |
| gdc.oaire.influence | 1.03297415E-8 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Cell cycle alteration | |
| gdc.oaire.keywords | cell cycle alteration | |
| gdc.oaire.keywords | Cell Cycle | |
| gdc.oaire.keywords | apoptosis | |
| gdc.oaire.keywords | Antineoplastic Agents | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Multidrug resistance | |
| gdc.oaire.keywords | bioactive sphingolipids | |
| gdc.oaire.keywords | Drug Resistance, Multiple | |
| gdc.oaire.keywords | Membrane Lipids | |
| gdc.oaire.keywords | ABC transporters | |
| gdc.oaire.keywords | multidrug resistance | |
| gdc.oaire.keywords | Neoplasms | |
| gdc.oaire.keywords | Bioactive sphingolipids | |
| gdc.oaire.keywords | cancer | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Cancer | |
| gdc.oaire.popularity | 1.4488381E-7 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.views | 154 | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 7.319 | |
| gdc.openalex.normalizedpercentile | 0.98 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 289 | |
| gdc.plumx.crossrefcites | 173 | |
| gdc.plumx.mendeley | 241 | |
| gdc.plumx.pubmedcites | 136 | |
| gdc.plumx.scopuscites | 298 | |
| gdc.scopus.citedcount | 298 | |
| gdc.virtual.author | Adan, Aysun | |
| relation.isAuthorOfPublication | 523d8b8a-2c15-4d43-adcc-23a09e0f2e75 | |
| relation.isAuthorOfPublication.latestForDiscovery | 523d8b8a-2c15-4d43-adcc-23a09e0f2e75 | |
| relation.isOrgUnitOfPublication | 665d3039-05f8-4a25-9a3c-b9550bffecef | |
| relation.isOrgUnitOfPublication | 4eea69bf-e8aa-4e3e-ab18-7587ac1d841b | |
| relation.isOrgUnitOfPublication | f1a6e7de-5c27-471c-ada8-77b7e5558b19 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 665d3039-05f8-4a25-9a3c-b9550bffecef |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Molecular mechanisms of drug resistance and its reversal in cancer (1).pdf
- Size:
- 658.53 KB
- Format:
- Adobe Portable Document Format
- Description:
- Makale Dosyası
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.44 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
